Abbott Laboratories (NYSE:ABT) Given New $140.00 Price Target at Citigroup

Abbott Laboratories (NYSE:ABT) had its price target lowered by Citigroup from $155.00 to $140.00 in a research report report published on Friday,Benzinga reports. Citigroup currently has a buy rating on the healthcare product maker’s stock.

ABT has been the topic of several other research reports. BTIG Research cut their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a report on Friday. Sanford C. Bernstein reduced their price target on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday. Raymond James Financial dropped their price objective on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a report on Friday. Royal Bank Of Canada reduced their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday. Finally, Mizuho raised their price target on shares of Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Tuesday, October 14th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $140.79.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $107.46 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The company has a market capitalization of $186.86 billion, a price-to-earnings ratio of 28.89, a price-to-earnings-growth ratio of 1.80 and a beta of 0.72. The company’s 50 day simple moving average is $124.77 and its 200-day simple moving average is $128.36. Abbott Laboratories has a 1 year low of $105.78 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the firm earned $1.34 EPS. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s payout ratio is currently 67.74%.

Hedge Funds Weigh In On Abbott Laboratories

Several large investors have recently bought and sold shares of ABT. Bingham Private Wealth LLC acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $439,000. Farther Finance Advisors LLC boosted its holdings in Abbott Laboratories by 45.4% in the fourth quarter. Farther Finance Advisors LLC now owns 62,150 shares of the healthcare product maker’s stock valued at $7,787,000 after purchasing an additional 19,410 shares in the last quarter. Freestone Capital Holdings LLC increased its stake in Abbott Laboratories by 0.4% in the fourth quarter. Freestone Capital Holdings LLC now owns 134,161 shares of the healthcare product maker’s stock valued at $16,809,000 after purchasing an additional 540 shares during the last quarter. Octavia Wealth Advisors LLC raised its holdings in Abbott Laboratories by 6.0% during the fourth quarter. Octavia Wealth Advisors LLC now owns 3,115 shares of the healthcare product maker’s stock worth $390,000 after purchasing an additional 176 shares in the last quarter. Finally, Cura Wealth Advisors LLC lifted its position in shares of Abbott Laboratories by 0.3% during the 4th quarter. Cura Wealth Advisors LLC now owns 227,873 shares of the healthcare product maker’s stock worth $28,550,000 after buying an additional 622 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: MedTech and pharma strength, and EPS resilience — Abbott reported adjusted Q4 EPS growth (company highlighted margin improvements) and strong MedTech (+~12%) and Established Pharma (+~9%) performance that partly offset Nutrition weakness; management still projects FY‑2026 adjusted EPS growth. Press Release
• Positive Sentiment: Analysts keep buy/outperform stance despite cuts — several major firms trimmed price targets after the print but largely maintained buy/overweight ratings, signaling conviction in the longer‑term story even as near‑term expectations were tempered. Analyst Reaction
• Positive Sentiment: Some commentators view the pullback as a buying opportunity — market commentators highlight ABT’s dividend history, cash flow and buyback capacity, suggesting the drop may create an attractive entry for long‑term investors. MarketBeat: Pullback Analysis
• Neutral Sentiment: Full earnings call and transcripts available — investors can review management commentary and segment detail in the Q4 earnings call transcript for color on nutrition, diagnostics and Exact/other strategic items. Earnings Transcript
• Neutral Sentiment: Dividend/valuation commentary circulates — value and dividend‑focused outlets are flagging ABT as attractively valued after the pullback; this is background context rather than a near‑term catalyst. Zacks: Value Take
• Negative Sentiment: Revenue miss driven by Nutrition and Diagnostics — Q4 revenue (~$11.5B) fell short of consensus, with Nutrition down sharply (~8–9%) and Diagnostics weak, sparking the initial selloff. Reuters: Revenue Miss
• Negative Sentiment: Guidance slightly below Street — Abbott set Q1 EPS and FY‑2026 EPS ranges that sit near or a touch below consensus, increasing near‑term revenue/growth concerns. Guidance Details
• Negative Sentiment: Multiple price‑target cuts — a raft of firms (Citigroup, Goldman, Raymond James, Sanford Bernstein, Oppenheimer, RBC, etc.) trimmed targets, which can amplify selling pressure even if ratings remain constructive. Benzinga: PT Cuts
• Negative Sentiment: Options and hedging activity spiked — an unusual surge in put buying suggests traders are positioning for further near‑term downside (heightened bearish sentiment).
• Negative Sentiment: Regulatory scrutiny in India — reports of an investigation into alleged misuse of a codeine‑based cough syrup (Abbott Healthcare) add an extra headline risk in emerging markets. Reuters: India Scrutiny

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.